Emisphere Technologies, Inc. to Hold Conference Call to Discuss First Quarter 2001 Financial Results

Apr 19, 2001, 01:00 ET from Emisphere Technologies, Inc.

    TARRYTOWN, N.Y., April 19 /PRNewswire/ --
 Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to
 discuss the Company's first quarter financial results for the period ending
 March 31, 2001, following its recent transition to a calendar year financial
 reporting period. The call will be held on Tuesday, May 1, 2001, beginning at
 10:30 a.m. Eastern time (7:30 a.m. Pacific). A replay of the call will be
 accessible approximately 2 hours following the end of the call and will be
 archived for 72 hours.
 
      The live conference call dial-in number is:
 
      877-282-2316 (domestic callers)
      703-871-3029 (international callers)
 
      To access a replay of the call:
 
      888-266-2081 (domestic callers)
      703-925-2578 (international callers)
 
      Reservation Number:   5121820
 
     Emisphere will simultaneously be webcasting this teleconference.  To
 access the conference in listen-only mode please go to the investor relations
 portion of the Company's website:  http://www.emisphere.com/investor/.  Please
 visit the site at least five minutes prior to start time for instructions.
     Emisphere Technologies, Inc., is a biopharmaceutical company pioneering
 the oral delivery of otherwise injectable drugs.  By applying its unique
 carrier technology, Emisphere has taken a leadership position in solving the
 oral delivery of proteins, peptides and other macromolecules produced by both
 pharmaceutical and biotechnology companies.  Three Emisphere formulations are
 currently in human clinical trials being conducted by Emisphere and its
 partners.  Emisphere develops pharmaceutical products for its own portfolio
 and has several strategic alliances and ongoing feasibility studies with many
 of the world's leading pharmaceutical and biotechnology companies, including
 Novartis Pharma AG, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc. and
 Cubist Pharmaceuticals, Inc.  For further information, please visit
 Emisphere's website at http://www.emisphere.com.
 
 

SOURCE Emisphere Technologies, Inc.
    TARRYTOWN, N.Y., April 19 /PRNewswire/ --
 Emisphere Technologies, Inc. (Nasdaq: EMIS) will hold a conference call to
 discuss the Company's first quarter financial results for the period ending
 March 31, 2001, following its recent transition to a calendar year financial
 reporting period. The call will be held on Tuesday, May 1, 2001, beginning at
 10:30 a.m. Eastern time (7:30 a.m. Pacific). A replay of the call will be
 accessible approximately 2 hours following the end of the call and will be
 archived for 72 hours.
 
      The live conference call dial-in number is:
 
      877-282-2316 (domestic callers)
      703-871-3029 (international callers)
 
      To access a replay of the call:
 
      888-266-2081 (domestic callers)
      703-925-2578 (international callers)
 
      Reservation Number:   5121820
 
     Emisphere will simultaneously be webcasting this teleconference.  To
 access the conference in listen-only mode please go to the investor relations
 portion of the Company's website:  http://www.emisphere.com/investor/.  Please
 visit the site at least five minutes prior to start time for instructions.
     Emisphere Technologies, Inc., is a biopharmaceutical company pioneering
 the oral delivery of otherwise injectable drugs.  By applying its unique
 carrier technology, Emisphere has taken a leadership position in solving the
 oral delivery of proteins, peptides and other macromolecules produced by both
 pharmaceutical and biotechnology companies.  Three Emisphere formulations are
 currently in human clinical trials being conducted by Emisphere and its
 partners.  Emisphere develops pharmaceutical products for its own portfolio
 and has several strategic alliances and ongoing feasibility studies with many
 of the world's leading pharmaceutical and biotechnology companies, including
 Novartis Pharma AG, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc. and
 Cubist Pharmaceuticals, Inc.  For further information, please visit
 Emisphere's website at http://www.emisphere.com.
 
 SOURCE  Emisphere Technologies, Inc.